Market Intelligence, Clinical Progress, and High-Purity Reagents for IgA Nephropathy and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGHA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGHA1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IGHA1 Products |
| Gene Delivery | IGHA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View IGHA1 Products |
| Benchmark Ab | Anti-IGHA1 Recombinant Antibody Sequence-verified positive control for assay development. |
View IGHA1 Products |
| Validator | IGHA1 siRNA Set Target-specific knockdown verification in cellular assays. |
View IGHA1 Products |
| Related Target A | FCAR (CD89) The primary Fc receptor for IgA, critical for evaluating IgA-mediated effector functions and clearance. |
View FCAR Products |
| Related Target B | TNFSF13 (APRIL) Key cytokine driving IgA class-switching, a major upstream therapeutic target in IgA Nephropathy. |
View TNFSF13 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycoform-specific binding (Gd-IgA1 vs normal IgA1) | HEK293 expressed IGHA1 with native, verified O-glycosylation profiles. |
| FCAR receptor binding affinity evaluation | High-purity monomeric and dimeric IGHA1 and FCAR proteins optimized for SPR/BLI. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IGHA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGHA1 therapeutics is intensifying, with major players shifting focus from traditional immunosuppression to targeted biological modulation in IgA Nephropathy (IgAN) and novel IgA-based oncology platforms. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific pathogenic glycoforms (Galactose-deficient IgA1, or Gd-IgA1) and leveraging the IgA-FCAR axis for neutrophil-driven tumor clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Anti-Gd-IgA1) | Otsuka/Visterra, Chinofit | IgA Nephropathy (IgAN) | Selectivity Assay (Need high-purity WT IGHA1 vs Gd-IgA1) |
| IgA Proteases (Enzymatic) | Novartis (Chinook), Ibis | Glomerulonephritis | Cleavage Assay (Need sequence-verified, intact IGHA1 substrate) |
| IgA-based Oncology mAbs | Takeda, Academic Spin-offs | Solid Tumors | FCAR Binding & ADCC Assay (Need high-purity FCAR and IGHA1) |